Sohn delivers lessons on tech disruption

From e-signatures to last-mile logistics and facials, the annual conference showed that waves of disruption continue to break in different ways across different sectors.

James Thomson

Sohn delivers lessons on tech disruption

December 3, 2021
From e-signatures to last-mile logistics and facials, the annual conference showed that waves of disruption continue to break in different ways across different sectors.
Read Transcript

At first glance, the links between a Japanese e-signature company, a US beauty group and a German delivery giant might not be obvious. But the annual Sohn Hearts & Minds Conference, held virtually on Friday, provided a reminder that while we all live in an online world, waves of tech disruption are still breaking across sectors everywhere – but in very different waves.

The last-mile logistics industry has become such a part of our lives during COVID-19 that you might think there’s limited room for more disruption. But Beeneet Kothari of New York’s Tekne Capital Management sees a new wave coming as consumer expectations move from getting their takeaway, groceries or small parcels in a week to a day, to an hour, to 15 minutes.

His top way to play this is German giant Delivery Hero, which he says has been marked down by investors because of the losses that have come from heavy investment in employing its own delivery drivers, rather than using third parties. But Kothari believes this group will soon be profitable and can ride the surging demand for convenience to triple gross sales to more than $105 billion in the next four or five years.

That alone could see the stock double, Kothari argues. But if the stock were re-rated to trade on multiples similar to that of rivals such as Chinese group Meituan and US group DoorDash, there could be gains of 400 per cent to 500 per cent for the patient investor.

‍While Delivery Hero is part of a third wave of disruption in the last-mile logistics space (disrupting the disruptors who disrupted the original players), Flight Deck Capital’s pick was about disrupting a practice unchanged for centuries.

Silicon Valley legend Jay Kahn, who founded Flight Deck Capital last year after a long stint at Light Street Capital, explained how Japan’s reliance on what are called hanko stamps to certify official documents has slowed the adoption of e-signature, as has occurred in the US and even in Australia.

But COVID-19 has changed the game, with the Japanese government saying this year it would allow e-signatures on government documents, and the financial services sector starting to follow.

Khan believes he has spotted the Japanese version of DocuSign, the $US56 billion ($79.5 billion) leader of the US e-signature market (well, it was worth $US56 billion until an untimely earnings downgrade on Thursday night saw its stock plunge almost 30 per cent in after-hours trade), in a company called Bengo4.com, which is worth $1.8 billion.‍

Flight Deck values the Japanese e-signature market at just $126 million currently, but believes it can climb towards $1 billion if the sort of penetration in the US is replicated in Japan.

If Bengo4 can lift market penetration to 5.5 per cent from 1.5 per cent, Khan believes the stock can double, and if penetration tops 6 per cent, it could possibly triple.

‍Joyce Meng’s stock pick wasn’t a tech company, but tech has become crucial to its growth. The US-based founder of FACT Capital tipped Beauty Health Co, a stock up 137 per cent in the past 12 months on the back of the growth of its flagship product, HydraFacial.

The monthly beauty treatment, which costs about $280 each time, has become famous on social media for customers posting shots of their skin afterwards (with the hashtag HydraGlow, of course) and pictures of the bags of grossness (dead skin, old blackheads and grime) that the treatment leaves behind. Ain’t technology grand.

Meng likes the razor/razor blade model that means the company makes money both from selling the machines essential for the treatment and from each treatment itself. A beauty therapist will generally be paid back for the cost of the $42,000 machine in 11 months at the most, and will also benefit from attracting younger customers.

‍Meng can see organic growth of 30 per cent in the coming years as Beauty Health sells more machines, which seems achievable given growth pre-COVID-19 was running at 52 per cent, and growth during COVID-19 was 39 per cent. The company also has $1.3 billion for M&A and a big range of new products coming out next year.

‍FACT has a price target of $US42 on the stock, or about 43 per cent higher than its current price.

This article was originally posted by The AFR here.

Licensed by Copyright Agency. You must not copy this work without permission.

At first glance, the links between a Japanese e-signature company, a US beauty group and a German delivery giant might not be obvious. But the annual Sohn Hearts & Minds Conference, held virtually on Friday, provided a reminder that while we all live in an online world, waves of tech disruption are still breaking across sectors everywhere – but in very different waves.

The last-mile logistics industry has become such a part of our lives during COVID-19 that you might think there’s limited room for more disruption. But Beeneet Kothari of New York’s Tekne Capital Management sees a new wave coming as consumer expectations move from getting their takeaway, groceries or small parcels in a week to a day, to an hour, to 15 minutes.

His top way to play this is German giant Delivery Hero, which he says has been marked down by investors because of the losses that have come from heavy investment in employing its own delivery drivers, rather than using third parties. But Kothari believes this group will soon be profitable and can ride the surging demand for convenience to triple gross sales to more than $105 billion in the next four or five years.

That alone could see the stock double, Kothari argues. But if the stock were re-rated to trade on multiples similar to that of rivals such as Chinese group Meituan and US group DoorDash, there could be gains of 400 per cent to 500 per cent for the patient investor.

‍While Delivery Hero is part of a third wave of disruption in the last-mile logistics space (disrupting the disruptors who disrupted the original players), Flight Deck Capital’s pick was about disrupting a practice unchanged for centuries.

Silicon Valley legend Jay Kahn, who founded Flight Deck Capital last year after a long stint at Light Street Capital, explained how Japan’s reliance on what are called hanko stamps to certify official documents has slowed the adoption of e-signature, as has occurred in the US and even in Australia.

But COVID-19 has changed the game, with the Japanese government saying this year it would allow e-signatures on government documents, and the financial services sector starting to follow.

Khan believes he has spotted the Japanese version of DocuSign, the $US56 billion ($79.5 billion) leader of the US e-signature market (well, it was worth $US56 billion until an untimely earnings downgrade on Thursday night saw its stock plunge almost 30 per cent in after-hours trade), in a company called Bengo4.com, which is worth $1.8 billion.‍

Flight Deck values the Japanese e-signature market at just $126 million currently, but believes it can climb towards $1 billion if the sort of penetration in the US is replicated in Japan.

If Bengo4 can lift market penetration to 5.5 per cent from 1.5 per cent, Khan believes the stock can double, and if penetration tops 6 per cent, it could possibly triple.

‍Joyce Meng’s stock pick wasn’t a tech company, but tech has become crucial to its growth. The US-based founder of FACT Capital tipped Beauty Health Co, a stock up 137 per cent in the past 12 months on the back of the growth of its flagship product, HydraFacial.

The monthly beauty treatment, which costs about $280 each time, has become famous on social media for customers posting shots of their skin afterwards (with the hashtag HydraGlow, of course) and pictures of the bags of grossness (dead skin, old blackheads and grime) that the treatment leaves behind. Ain’t technology grand.

Meng likes the razor/razor blade model that means the company makes money both from selling the machines essential for the treatment and from each treatment itself. A beauty therapist will generally be paid back for the cost of the $42,000 machine in 11 months at the most, and will also benefit from attracting younger customers.

‍Meng can see organic growth of 30 per cent in the coming years as Beauty Health sells more machines, which seems achievable given growth pre-COVID-19 was running at 52 per cent, and growth during COVID-19 was 39 per cent. The company also has $1.3 billion for M&A and a big range of new products coming out next year.

‍FACT has a price target of $US42 on the stock, or about 43 per cent higher than its current price.

This article was originally posted by The AFR here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Australian Financial Review, published on Dec 03, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More
July 21, 2024

Investors ‘comfortable’ about a Trump presidency, despite volatility

Economists and market experts say the outcome of the US presidential election has been largely priced in by investors as softening inflation helps to buoy sharemarkets both globally and locally.

Read More
Qiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar Colman
May 28, 2024

The AI bulls are sticking to Nvidia despite 600pc share price rally

Nvidia’s quarterly earnings once again exceeded analysts’ expectations and Portfolio Manager, Qiao Ma of Munro Partners says the rise is “nowhere close to being over”.

Read More
Munro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke Meitzel
February 15, 2024

Hedge fund Munro says Nvidia, Microsoft have more to run

Kieran Moore is portfolio manager of Munro Partners Global Growth Fund. The Melbourne-based hedge fund oversees $4.3 billion in assets.

Read More
January 24, 2024

How To Master The Art Of Winning The Room

Jonathan Pease, the creative director behind the Sohn Hearts & Minds Conference and author of the book, Winning the Room, recently sat down for a chat with Mark Bouris on Straight Talk.

Read More
2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 
January 19, 2024

Best funds of 2023 stick with bitcoin, big tech bets

Some of the best performing funds of 2023 are holding firm on bitcoin and mega-cap tech stock picks that made them big money last year.

Read More
November 19, 2023

Equity Mates review the stocks pitched at the Sohn Hearts & Minds Conference

Bryce and Ren of Equity Mates attended the Sohn Hearts & Minds Conference and reviewed the stocks pitched by our new 2023 Conference Fund Managers.

Read More
Ark Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David Rowe
November 17, 2023

‘I Know It Sounds Crazy’: Cathie Wood’s Next Big Idea

Speaking from Ark’s headquarters in Florida ahead of her appearance at the Sohn Hearts & Minds Conference on Friday, Wood says she believes disinflation is now just around the corner in the US.

Read More
ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.
November 17, 2023

ARK Founder Wood Backs Bitcoin, Banking On Spot ETF Approval

Tech investment guru Cathie Wood is still a big believer in bitcoin, so it was fitting that she chose Grayscale Bitcoin Trust as her stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
IFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee Nowytarger
November 17, 2023

Hot Stocks To Ride The Next Healthcare Trends

Healthcare stocks – from sleep apnoea giant ResMed, to cancer diagnostic biotech Telix Pharmaceuticals – were recommended at the Sohn Hearts & Minds Investment Leaders Conference on Friday.

Read More
November 17, 2023

How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

Read More
November 17, 2023

The 12 Hottest Stock Tips From This Year’s Sohn Experts

It might be time to look beyond big names. That was the message from top fund managers, company founders and super funds at the Sohn Hearts & Minds.

Read More
Azora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee Nowytarger
November 17, 2023

Webster Financial ‘Avoided The Mistakes Of US Bank Failures’

The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
November 17, 2023

Why Stock Picker Cathie Wood Of ARK Can’t Stand Google

The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.